Cerebrospinal fluid S100B levels reflect symptoms of depression in patients with non-inflammatory neurological disorders
Authors:
- Tomas UherTUTomas Uher
- Petr BobPBPetr Bob
- 1 November 2012
- journal article
- Published by Elsevier in Neuroscience Letters
- Vol. 529 (2) , 139-143
Abstract
No abstract availableKeywords
Funding Information
- Ministerstvo Školství, Mládeže a Tělovýchovy (MSM0021620849)
- Grantová Agentura České Republiky (P407/12/1957)
This publication has 38 references indexed in Scilit:
- Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disordersNeuroscience Letters, 2011
- Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depressionMolecular Psychiatry, 2010
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like BehaviorsBiological Psychiatry, 2008
- Circulating Levels of Soluble Receptor for Advanced Glycation End Products in Alzheimer Disease and Vascular DementiaArchives of Neurology, 2005
- S100B and response to treatment in major depression: a pilot studyEuropean Neuropsychopharmacology, 2003
- S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional rolesThe International Journal of Biochemistry & Cell Biology, 2001
- S100b expression in and effects on microgliaGlia, 2001
- Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) ActivationJournal of Biological Chemistry, 2000
- The twenty-item Toronto Alexithymia scale—II. Convergent, discriminant, and concurrent validityJournal of Psychosomatic Research, 1994